Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes after intraperitoneal injection

Acta Oncologica

Volumn 42, Issue 2, 2003, Pages 147-153

  Syrigos, Konstantinos N ^a   Vile, Richard G ^b   Peters, A Michael ^c   Harrington, Kevin J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MAYO CLINIC   (United States)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DISEASES; TUMORS;

BIODISTRIBUTION;

ONCOLOGY;

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INDIUM 111; LIPOSOME; PACLITAXEL; PENTETIC ACID; DRUG CARRIER; INDIUM;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG FORMULATION; FEMALE; GALLBLADDER; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; OTOTOXICITY; OVARY; PANCREAS; PERITONEUM; PRIORITY JOURNAL; SIDE EFFECT; SMALL INTESTINE; STOMACH; ANIMAL; BLOOD; CHEMISTRY; DRUG DELIVERY SYSTEM; GERMFREE ANIMAL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; TISSUE DISTRIBUTION; URINE;

ADRENAL GLANDS; ANIMALS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; COLON; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; GALLBLADDER; INDIUM RADIOISOTOPES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INTESTINE, SMALL; LIPOSOMES; MICE; OVARY; PANCREAS; PENTETIC ACID; PERITONEUM; SPECIFIC PATHOGEN-FREE ORGANISMS; STOMACH; TISSUE DISTRIBUTION;

EID: 0038702372     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310005697     Document Type: Article

References (26)

1. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-5.
2. Buchsbaum HJ, Keettel WC. Radioisotopes in treatment of stage Ia ovarian cancer. Natl Cancer Inst Monogr 1975; 42: 127-8.
3. Edwards RP, Gooding W, Lembersky BC, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 1997; 15: 3399-407.
4. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68: 403-6.
5. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a gynecologic oncology group pilot study. J Clin Oncol 1995; 13: 2961-7.
6. Lasic DD, Papahadjopoulos D. Liposomes revisited. Science 1995; 267:1275-6.
7. Huang SK, Lee K-D, Hong K, Friend DS, Papahadjopoulos D. Microscopic localisation of sterically stabilised liposomes in colon carcinoma-bearing mice. Cancer Res 1992; 52: 5135-43.
8. Harrington KJ. Liposomal cancer chemotherapy: current clinical applications and future prospects. Expert Opin Invest Drugs 2001; 10: 1045-61.
9. Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst 1995; 87: 1556-7.
10. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Vile RG, Stewart JSW. Pegylated liposomes have potential as vehicles for intratumoural and subcutaneous drug delivery. Clin Cancer Res 2000; 6: 2528-37.
11. Gondal JA, Preuss HG, Swartz R, Rahman A. Comparative pharmacological, toxicological and antitumoural evaluation of free and liposome-encapsulated cisplatin in rodents. Eur J Cancer 1993; 29A: 1536-42.
12. Sharma A, Mayhew E, Bolcsak L, et al. Activity of paclitaxel liposome formulations against human ovarian tumour xenografts. Int J Cancer 1997; 71: 103-7.
13. Sharma A, Sharma US, Straubinger RM. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukaemia. Cancer Lett 1996; 107: 265-72.
14. Vaage J, Donovan D, Mayhew E, Abra R, Huang A. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilised liposomes. Cancer 1993; 72: 3671-5.
15. Vadiei K, Siddik ZH, Khokhar AR, al-Baker S, Sampedro F, Perez-Soler R. Pharmacokinetics of liposome-entrapped cisbis-neodecanoato trans-R, R-1,2 diaminocyclohexane platinum (II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol 1992; 30: 365-9.
16. Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A. Comparative study of the antitumour activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res 1998; 4: 499-505.
17. Delgado G, Potkul RK, Treat JA, et al. A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. Am J Obstet Gynecol 1989; 160: 812-7.
18. Perez-Soler R, Shin DM, Siddik ZH, et al. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res 1997; 3: 373-9.
19. 111/In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer 2000; 83: 232-8.
20. Harrington KJ, Mohammadtaghi S, Uster PS, Glass DM, Peters AM, Vile RG, Stewart JSW. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001; 7: 243-54.
21. O'Dwyer PJ, LaCreta F, Hogan M, Rosenblum N, O'Dwyer JL, Comis RL. Pharmacologic study of etoposide and cisplatin by the intraperitoneal route. J Clin Pharmacol 1991; 31: 253-8.
22. Malviya VK, Deppe G, Boike G, Young J. Pharmacokinetics of intraperitoneal doxorubicin in combination with systemic cyclophosphamide and cis-platinum in the treatment of stage III ovarian cancer. Gynecol Oncol 1990; 36: 185-8.
23. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumour activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-93.
24. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000; 78: 369-72.
25. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093-100.
26. Kim S, Kim DJ, Howell SB. Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes. Cancer Chemother Pharmacol 1987; 19: 307-10.